We will also cover the clinical requirements for eligibility and what it looks like when you take the free assessment quiz as the first step in the process
2020 Jan-Dec;19:1536012120952623
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
Novo Nordisk reported the results from the STEP 1 extension trial on the impact of treatment withdrawal, which found that one year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss
This trend has boosted interest in medications, not just lifestyle changes, for weight management
Additionally, GLP-1 enhances cognitive function, improves memory and exerts neuroprotective effects (50,51)